Table 1. Patients’ characteristics in different groups.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristics  | latent CMV infection | subclinical CMV infection  | CMV disease |  p value |
| (n=50) | (n=26) | (n=24) |
| Age (Mean ± SD) | 46 ± 16 | 45 ± 16 | 43 ± 16  | 0.673 |
| Male, n (%） | 38 (76.0） | 24 (92.3) | 17 (70.8) | 0.137 |
| autoimmune disease, n (%) | 50 (100.0) | 26 (100.0) | 24 (100.0) | / |
| Glucocorticoid used within 3 months, n (%) | 47 (94.0) | 26 (100.0) | 24 (100.0) | 0.216 |
| Immunosuppressive used within 3 months, n (%) | 39 (78.0) | 22 (84.6) | 19 (79.2)  | 0.788 |
| biological agents used within 3 months, n (%) | 4 (8.0) | 2 (7.7) | 2 (8.3) | 0.997 |
| CMV IgG positive, n (%) | 50 (100.0) | 25 (96.1) | 24 (100.0) | / |
| CMV IgM positive, n (%) | 0 (0) | 3 (11.5) | 0 (0) | / |
| Lymphocyte count (/uL), [median (IQR）] | 1115 (710-1892) | 940 (582-1742) | 585 (315-1300) | 0.003 |
| CD4 + T cell count (/uL), [median (IQR）] | 318 (168-745) | 420 (197-545) | 155 (86-465) | 0.149 |
| CD8 + T cell count (/uL), [median (IQR）] | 335 (215-535) | 296 (198-807) | 254 (152-360) | 0.379 |

Mean ± SD: mean ± standard deviation; median (IQR): median (interquartile interval)